SOARD revealed
numerous unmet
needs in H. pylori

Discover SOARD’s real-world data on the complexity and burdens of H. pylori treatment¹

Watch as Dr Colin Howden shares real-world insights from SOARD.^a

Learn important takeaways from SOARD, including:

•Most physicians typically choose a standard-of-care PPI-based triple therapy as first-line regimen
•Complexity of current regimens can contribute to low patient adherence
•Physicians and patients are not completely satisfied with current treatments

Get even more insights on the burden of H. pylori from HCPs and patients¹:

Over the last decade, eradication rates have
dropped to ≤76%²

Although numerous treatment options are available, eradication rates with current first-line treatments have declined.¹

eradication rates

eradication rates

^a

Indicates percentage of physicians with a response of 6 or 7 on a 7-point scale that ranged from (1) completely disagree to (7) completely agree to the statement: “Increased eradication rates are the most important need in Helicobacter pylori management.”³

Expand the next section to see even more real-world data.

The top 3 treatment goals for doctors and patients are different

How do you and your patients prioritize concerns compared to SOARD results?

Doctors may have different priorities in diagnosing H. pylori

SOARD real-world data revealed low use of noninvasive testing methods across specialties.¹

Why were only 60% of H. pylori patients in SOARD treatment-adherent?¹

Discover the reasons adherence is a significant issue.

Neither HCPs nor their patients are satisfied with current treatment options¹

SOARD real-world data indicate a need for more therapeutic options:

Explore real-world data
in the SOARD publication.

SOARD

Go to Publication

Get even more insights on acid-related
disorders from Dr Colin Howden.

SOARD

^a

SOARD (Study of Acid-Related Disorders, Perspectives From Physicians and Patients), a Phathom Pharmaceuticals–sponsored study that surveyed 251 physicians (102 gastroenterologists, 149 primary care physicians) and 77 patients with H. pylori infection with dyspepsia between November 2020 and April 2021. The survey captured physician and patient perspectives on symptoms, burden of disease, treatment goals, adherence, and satisfaction. A medical chart review was conducted for all patients. The differences in physician perception and patient experience of the disease have been analyzed, as well as patient demographics, clinical characteristics, and disease and treatment management.

References:

1.Howden CW, Spechler SJ, Vaezi MF, et al. Study of acid-related disorders: real-world physician and patient perspectives on burden of Helicobacter pylori infection. Gastro Hep Advances. 2022;1:231-240.
2.Mertz A, Manish S, Pak K, et al. Helicobacter pylori treatment eradication rates in department of defense patients from 2016-2018. Am J Gastroenterol. 2020:S1319. doi: 10.14309/ajg.0000000000000862
3.Data on file. Phathom Pharmaceuticals, Inc. Florham Park, NJ.

Register for information and updates